tradingkey.logo

Neurogene Announces Evidence-Based Monitoring And Treatment Intended To Reverse Rare Hyperinflammatory Syndrome Associated With High-Dose Aav

ReutersMay 16, 2025 11:32 AM

- Neurogene Inc NGNE.O:

  • NEUROGENE ANNOUNCES EVIDENCE-BASED MONITORING AND TREATMENT INTENDED TO REVERSE RARE HYPERINFLAMMATORY SYNDROME ASSOCIATED WITH HIGH-DOSE AAV

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI